Kenvue stock
Price history
+35.60% over the period1 year: from $14.24 (October 30, 2025) to $19.31 (October 30, 2026), +35.60%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| October 30, 2026 | $19.31 |
| September 30, 2026 | $17.66 |
| August 31, 2026 | $18.88 |
| July 31, 2026 | $19.24 |
| June 30, 2026 | $19.11 |
| May 29, 2026 | $17.28 |
| April 30, 2026 | $17.53 |
| March 31, 2026 | $17.24 |
| February 27, 2026 | $19.12 |
| January 30, 2026 | $17.40 |
| December 31, 2025 | $17.25 |
| November 28, 2025 | $17.35 |
| October 31, 2025 | $14.37 |
| October 30, 2025 | $14.24 |
At a glance
The company
Consumer health company offering over-the-counter medicines, self-care products, skin and beauty care, and essential health products across multiple brands
Latest results
Quarter to September 30, 2026 · EPS $0.22 (estimate $0.37)
TickerLandia's take on Kenvue
- Cheaper than similar companies: trailing 12-month P/E 22 vs 26 (−16%) in a group of 11.
- Strong point: Dividend (61/100 in its group). Weak point: Financial strength (22/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−4.07% from the 52-week high
Analysts · 12 analysts
Average target$19.50+0.98% vs. price
Buy 2 · Hold 10 · Sell 0 · Hold
TickerLandia Fingerprint: Kenvue
Compared with similar companies: very low risk.
Financials and price compared with 27 companies in the household & personal products industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage47
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 15.6 33 P/E (trailing 12 months) 21.9 48 Price/sales 2.39 57 Price/book 3.65 48 EV/EBITDA 12.7 50 Profitabilityaverage57
How much it earns on revenue and capital.
Metric Value Position in group ROE 16.3% 50 ROA 7.0% 50 Operating margin 19.2% 65 Gross margin 58.5% 65 Net margin 10.9% 54 Earnings stabilityaverage50
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.8% 43 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 57 Growthaverage50
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +3.20% 52 Average revenue growth (3 years) +0.39% 35 Earnings growth (year over year) +6.00% 63 Financial strengthlow22
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 0.96 20 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.13 20 Interest coverage 6.48 17 Debt/equitycounts in reverse: lower means more financial strength 0.82 31 Dividendhigh61
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 94.9% 82 Consecutive dividend years at least 4 years 19 Dividend yield 4.4% 82 Market momentumaverage60
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −1.88% 42 Relative strength (6 months) +4.76% 53 1-year return +35.60% 79 Distance from 200-day average +6.15% 65 Riskvery low13
How much the price swings.
Metric Value Position in group Volatility (60 days) 21.4% 13 Beta (1 year) 0.08 21 Maximum drawdown (12 months) 13.3% 6
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Kenvue is cheaper than similar companies
Kenvue's P/E (trailing 12 months): 21.9, −16% against the median of a group of 11 similar companies (26.0).
Compared with 11 similar companies
| Metric | Kenvue | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 21.9 | Middle | |
| Forward P/E | 15.6 | Low | |
| Operating margin | 19.2% | Middle | |
| ROE | 16.3% | Middle | |
| Debt/equity | 0.82 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Kenvue. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$3.89B
Latest quarter · Q3 2026
Net income
$430M
Latest quarter · Q3 2026
Quarterly net margin
11.1%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $37.11B
- P/E
- 21.9
- EPS
- $0.88
- Volume
- 66.38M
- Daily trading
- €354.96M
- Dividend yield
- 4.32%
- Last ex-dividend on September 21, 2026
How Kenvue is changing
All resultsRevenue grew 0.9% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 138% of net income
Shares outstanding up 12.1% in 3 years
Returns
Kenvue returns with dividends
$1,000 invested in Kenvue 3 years ago, on October 30, 2023, would be worth $1,186 today with dividends reinvested: +18.59% in total, +5.85% per year. On price alone it would be $1,036 (+3.59%).
| Period | Kenvue | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +9.34% | −3.17% | $1,093 |
| 6 months | +10.15% | +5.15% | $1,102 |
| Year to date | +11.94% | +8.34% | $1,119 |
| 1 year | +43.75% | +11.11% | $1,437 |
| 3 years | +18.59% | +81.91% | $1,186 |
Over the last 6 months it has done better than 48% of the stocks in the Consumer sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Kenvue: technical analysis
Kenvue is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 29.8% below its all-time closing high ($27.50, May 15, 2023).
- Trend
- Upward
- RSI (14 sessions)
- 60
- Between 30 and 70
- vs 200-session average
- +6.15%
Support and resistance
Price areas where Kenvue has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$20.02+3.69%3 touches, last on October 22, 2026
- Last price$19.31
- Support$19.25−0.34%2 touches, last on August 14, 2026
- Support$18.67−3.31%4 touches, last on August 12, 2026
- Support$17.87−7.44%7 touches, last on June 22, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.08
- Volatility (60 sessions, annualised)
- 21.4%
- Largest fall in the last year
- −13.26%
Close of October 30, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Kenvue and its competitors
Consumers in the United States, the rest of North America, Europe, the Middle East, Africa, Asia-Pacific and Latin America are the markets served by Kenvue, a consumer health company. Its three segments are Self Care, Skin Health and Beauty, and Essential Health, covering over-the-counter medicines, skin and hair care, sun products, oral and baby care, women's health, wound care, tampons, cosmetics and vitamins. Brands in the portfolio include Tylenol, Neutrogena, Johnson's, Listerine, Zyrtec and BAND-AID.
- Headquarters
- Summit, United States
- Employees
- 21,780
- Founded
- 2022
- Chief executive
- Kirk Perry
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| KenvueKVUE | $37.11B | 19.2% | 21.9 | +10.15% |
| Estée Lauder CompaniesEL | $39.35B | 11.9% | 108.6 | +30.19% |
| Church And DwightCHD | $27.08B | 18.6% | 35.2 | +19.60% |
| Kimberly-ClarkKMB | $68.33B | 17.3% | 21.2 | +12.76% |
| Colgate-PalmoliveCL | $79.18B | 20.7% | 38.8 | +13.03% |
| CloroxCLX | $12.93B | 14.3% | 19.2 | +17.97% |
Same industry or related industries, similar size. Compare Kenvue with its competitors · Full profile
